The Center for Integrated Global Biomedical Sciences at the University at Buffalo To Establish COVID-19 Antibody Implementation Research Program
BUFFALO, NY – June 5, 2020- Dr. Gene D. Morse, Director of the Center for Integrated Global Biomedical Sciences at the University at Buffalo, is leading a COVID-19 Implementation Research Program that will investigate the use of rapid antibody testing and quantitative antibody testing at several locations including Western New York. The research program led by Dr. Morse, a State University of New York Distinguished Professor in the UB School of Pharmacy and Pharmaceutical Sciences, will initially evaluate leading-edge quantitative serology diagnostic equipment utilizing Watmind USA, Inc.’s state-of-the-art portable quantitative microfluidic chemiluminescent serology technology for SARS-CoV-2.
If successful, the implementation research will identify the role of rapid and quantitative testing for individuals with COVID-19, their family members and other high-risk groups. The project will also collaborate with regional programs (business, academic, government) to investigate the role for antibody testing in re-introducing the workforce and economic re-engagement for the region. As the project is established, additional laboratories that have validated quantitative antibody assays will be engaged to compare results from different antibody testing systems.
Watmind USA has donated its fourth generation, quantitative, microfluidic chemiluminescence M2 and M5 instruments as well as several thousand disposable lateral flow immunoassay disposable test kits and microfluidic reagent chips that are used to determine both COVID-19 antibody and antigen profiles. The M2 and M5 are the world’s first portable quantitative fourth-generation serology machines. Watmind USA has also filed an Emergency Use Authorization application with the U.S. Food and Drug Administration for its disposable rapid COVID-19 test kits. The research program will seek to enhance the region’s workforce planning while also nurturing a new international business collaboration with Watmind USA.
About Watmind USA, Inc.
Watmind USA is a US incorporated company (State of Wyoming), headquartered in Austin, Texas. The mission of Watmind USA is to educate, develop and distribute the best in class serology diagnostic products such as its M2 and M5, — the world’s first portable microfluidic chemiluminescence quantitative serology machines. Watmind USA is a leading developer of microfluidic chemiluminescent technology for serology testing, including solutions addressing the emergent COVID-19. Watmind USA’s serology research and development and research partners include the Wuhan Institute of Virology, providing unprecedented data access for open global viral research. (www.watmindusa.com)
About the Center for Integrated Global Biomedical Sciences at the University at Buffalo
The Center for Integrated Global Biomedical Sciences at the University at Buffalo brings together faculty from diverse research, clinical and applied programs to tackle important health issues. Center for Integrated Global Biomedical Sciences goals include: 1) developing an integrated global biomedical sciences research hub at the University at Buffalo by building collaborations among health profession schools with other decanal units, existing centers, institutes, and faculty communities of excellence in Buffalo and across the SUNY system, and 2) developing a sustainable development model for the Center for Integrated Global Biomedical Sciences that complements other research programs and builds synergies that advance the global reach of the university. The Center Director, Dr. Gene Morse, is also the co-director of the SUNY Global Health Institute and director of UB’s Global Virus Network – Center of Excellence. The Center for Integrated Global Biomedical Sciences also leads research and training programs sponsored by the Fogarty International Center at the National Institutes of Health in Jamaica, Zimbabwe and South Africa.
Kent Barrett, firstname.lastname@example.org, 310.373.0103
Marcene Robinson, email@example.com, 716.645.4595